VBL Therapeutics to Present Positive Phase 1/2 Data for VB-111 in Recurrent Platinum-Resistant Mullerian Cancer at ASCO Annual Meeting
13 mai 2015 17h01 HE
|
VBL Therapeutics
TEL AVIV, Israel, May 13, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Announces First Quarter 2015 Financial Results
12 mai 2015 08h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, May 12, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class...
VBL Therapeutics to Report First Quarter 2015 Financial Results on May 12, 2015
05 mai 2015 09h01 HE
|
VBL Therapeutics
TEL AVIV, Israel, May 5, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class...
VBL Therapeutics to Present Company Overview at Upcoming Conferences in May
29 avr. 2015 16h01 HE
|
VBL Therapeutics
TEL AVIV, Israel, April 29, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class...
VBL Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results
25 mars 2015 07h00 HE
|
VBL Therapeutics
-Will host conference call at 8:30 am ET today-
-Also announced positive top-line interim results for Phase 2b trial testing VB-111 in recurrent glioblastoma-
TEL AVIV, Israel, March 25, 2015...
VBL Therapeutics Reports Interim Topline Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM)
25 mars 2015 07h00 HE
|
VBL Therapeutics
TEL AVIV, Israel, March 25, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on March 25, 2015
19 mars 2015 17h23 HE
|
VBL Therapeutics
TEL AVIV, Israel, March 19, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of...
VBL Therapeutics to Present Company Overview at Upcoming Conferences in March
04 mars 2015 08h30 HE
|
VBL Therapeutics
TEL AVIV, Israel, March 4, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) a clinical-stage biotechnology company committed to the discovery, development and commercialization of...
VBL Therapeutics Announces Removal of FDA Partial Clinical Hold on VB-111
17 févr. 2015 07h30 HE
|
VBL Therapeutics
TEL AVIV, Israel, Feb. 17, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) a clinical-stage biotechnology company committed to the discovery, development and commercialization of...
VBL Therapeutics Reports Topline Results From Phase 2 Studies of VB-201 in Psoriasis and Ulcerative Colitis
17 févr. 2015 07h30 HE
|
VBL Therapeutics
-- Phase 2 Studies of VB-201 in Patients with Psoriasis and Ulcerative Colitis Did Not Meet Primary Endpoints --
-- Company to Continue Focus on VB-111 Development in rGBM with Phase 3 to Initiate...